Literature DB >> 2495221

Time-dependent interactions between 5-fluorouracil and mitomycin C on a human colon carcinoma cell line, HCT-8, in vitro.

O Russello, A Romanini, D Civalleri, R Rosso, A Nicolin, A Sobrero.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2495221     DOI： 10.1016/0277-5379(89)90273-3

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN： 0277-5379


× No keyword cloud information.
  7 in total

1.  A phase II study of mitomycin-C and S-1 as third-line chemotherapy in patients with advanced colorectal cancer.

Authors:  Jung Han Kim; Hyeong Su Kim; Dae Ro Choi; Geundoo Jang; Jung Hye Kwon; Ho Young Kim; Joo Young Jung; Hyo Jung Kim; Hun Ho Song; Yun Ho Shin; So Young Jung; Byung Chun Kim; Dae Young Zang
Journal:  Oncol Lett       Date:  2011-07-27       Impact factor: 2.967

2.  Neoadjuvant systemic fluorouracil and mitomycin C prior to synchronous chemoradiation is an effective strategy in locally advanced rectal cancer.

Authors:  I Chau; M Allen; D Cunningham; D Tait; G Brown; M Hill; K Sumpter; A Rhodes; A Wotherspoon; A R Norman; A Hill; A Massey; Y Prior
Journal:  Br J Cancer       Date:  2003-04-07       Impact factor: 7.640

3.  Resection of locally advanced pancreatic cancer after downstaging with continuous-infusion 5-fluorouracil, mitomycin-C, leucovorin, and dipyridamole.

Authors:  K E Todd; B Gloor; J S Lane; W H Isacoff; H A Reber
Journal:  J Gastrointest Surg       Date:  1998 Mar-Apr       Impact factor: 3.267

4.  Pegylated liposomal doxorubicin in combination with mitomycin C, infusional 5-fluorouracil and sodium folinic acid. A phase-I-study in patients with upper gastrointestinal cancer.

Authors:  R-D Hofheinz; A Willer; A Weisser; U Gnad; S Saussele; S Kreil; J T Hartmann; R Hehlmann; A Hochhaus
Journal:  Br J Cancer       Date:  2004-05-17       Impact factor: 7.640

5.  Combination chemotherapy in advanced gastrointestinal cancers: ex vivo sensitivity to gemcitabine and mitomycin C.

Authors:  P A Whitehouse; S J Mercer; L A Knight; F Di Nicolantonio; A O'Callaghan; I A Cree
Journal:  Br J Cancer       Date:  2003-12-15       Impact factor: 7.640

6.  Capecitabine in combination with mitomycin C in patients with gastrointestinal cancer: results of an extended multicentre phase-I trial.

Authors:  R-D Hofheinz; J T Hartmann; A Willer; K Oechsle; G Hartung; U Gnad; S Saussele; S Kreil; C Bokemeyer; R Hehlmann; A Hochhaus
Journal:  Br J Cancer       Date:  2004-08-31       Impact factor: 7.640

7.  Protracted infusional 5-fluorouracil plus high-dose folinic acid combined with bolus mitomycin C in patients with gastrointestinal cancer: a phase I/II dose escalation study.

Authors:  J T Hartmann; K Oechsle; D Quietzsch; A Wein; R D Hofheinz; F Honecker; O Nehls; C-H Köhne; G Käfer; L Kanz; C Bokemeyer
Journal:  Br J Cancer       Date:  2003-12-01       Impact factor: 7.640
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.